Anatomy of Collaboration in Pharma and R&D: Interview with IPSEN

ISSUE #64 – Singapore has positioned itself well as a leading medtech and biotech hub. In this interview, Emmanuel Montet, General Manager Singapore and ASEAN Director, Ipsen Specialty Care, shares with us about the company and its projects in Singapore.

 

What are IPSEN’s fields of expertise and activities in Singapore?

Emmanuel Montet picture- ipsen smart healthIpsen is a global specialty-driven pharmaceutical group that sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Our ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases.

Ipsen’s fields of expertise cover oncology, neurosciences and endocrinology. Our commitment to oncology is exemplified through a growing portfolio of key therapies that improve the care of patients suffering from prostate cancer, neuro-endocrine tumours, renal cell carcinoma and pancreatic cancer. We also have a significant presence in primary care.

We have been present in Singapore for two years and we are now a mid-sized enterprise here. We are consistently developing partnerships with local and international institutions, seeking to strengthen development of our products and advance scientific knowledge in various fields.

Ipsen’s fields of expertise cover oncology, neurosciences and endocrinology

 

Why have you chosen to set up in Singapore?

There are many factors that make Singapore a very favourable location, from the presence of a talent pool that is diversified, international and skilled in medical and technical aspects, to a working environment that is well-structured and pro-business. In addition, it is easy to get around the region through Singapore’s airport, and we are only a few hours away from the other countries in the region. This in fact is a great advantage for business developpers and business development.

 

Could you tell us about some of IPSEN’s projects in Singapore?

Partnerships are a key part of our R&D strategy, and we seek to strengthen our innovation capacity, notably by giving access to new and promising technologies and supporting the exploration of new research fields.

For example, we partnered in 2016 with the Institute of Molecular and Cell Biology (IMCB), a research institute under the aegis of the Agency for Science, Technology and Research (A*STAR), Singapore, to advance understanding and research of botulinum neurotoxin biology (BoNT).

By combining our expertise in BoNT recombinant engineering and biology with IMCB’s extensive knowledge and expertise in the fields of membrane and toxin trafficking and RNA interference screening, the collaboration aims to work on the key components of intracellular trafficking involved in the biological action of BoNTs. This work could potentially facilitate the design of new therapeutic toxins for addressing neurological disorders.

Another upcoming activity is a conference organised by the IPSEN Foundation that will take place in Singapore in February 2018. Dedicated to genome editing, it will be an exciting day to explore with partners here how we can advance research in this field.

Dedicated to genome editing, a conference organised by the IPSEN Foundation will take place in Singapore in February 2018

 

 


Ipsen is a global specialty-driven pharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients. Find out more about Ipsen on the Smart Health platform.

 

Interview with Emmanuel Montet, General Manager Singapore and ASEAN Director, Ipsen Specialty Care

Published in FOCUS Magazine — Issue #3 2017 “In the Pink of Health”

 

 

Smart Health Launched 2

exporter-simplanter-singapour-asie-2